DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Discovery of signalling molecules that mediate communication in the environment. This project aims to further our understanding of chemical compounds that mediate communication in the environment. The project will identify a broad range of new compounds that have significant potential to provide new products such as anti-bacterials, pesticides and plant growth regulators for the benefit of Australia.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE130100164
Funder
Australian Research Council
Funding Amount
$310,000.00
Summary
A facility for ex-vivo molecular imaging. The facility will allow a consortium of Australian researchers to create an integrated facility for imaging biological receptors in tissue, bringing together laboratory, radiochemistry and imaging expertise. Digital data at each site will be able to be viewed and analysed remotely.
Industrial Transformation Training Centres - Grant ID: IC210100040
Funder
Australian Research Council
Funding Amount
$4,997,903.00
Summary
ARC Training Centre for Facilitated Advancement of Australia's Bioactives (FAAB). The Centre for Facilitated Advancement of Australia's Bioactives (FAAB) will transform the rapidly growing bioactive ingredients sector. It will apply advanced analytical methods to molecular characterisation of bioactive products derived from foods, food-waste, and cell-based biotechnologies. FAAB will determine modes of action for bioactives with potential lifestyle and nutritional benefits allowing for evidence- ....ARC Training Centre for Facilitated Advancement of Australia's Bioactives (FAAB). The Centre for Facilitated Advancement of Australia's Bioactives (FAAB) will transform the rapidly growing bioactive ingredients sector. It will apply advanced analytical methods to molecular characterisation of bioactive products derived from foods, food-waste, and cell-based biotechnologies. FAAB will determine modes of action for bioactives with potential lifestyle and nutritional benefits allowing for evidence-informed decision-making, and regulatory framework development. FAAB graduates will lead and deliver future national self-reliance to the Australian bioactives sector, increasing diversification and international competitiveness and development of regulation in a growing market. Read moreRead less
Rational design of new drug candidates for the treatment of Trypanosoma cruzi infection. There is a serious shortage of safe and effective drugs to treat Chagas disease which is caused by a parasitic infection. This project aims to design and identify new drug candidates by defining the disposition profile within the body which is necessary to achieve a therapeutic effect.
The hidden secondary metabolite biosynthetic potential of fungi. This proposal aims to develop synthetic biology tools to allow rapid access to the hidden metabolites encoded in fungal genomes and discover how they interact with plant and animal hosts. Genome sequencing reveals that fungi harbour vast hidden potential for biosynthesis of bioactive small molecules. The lack of tools to efficiently access this hidden potential has hindered the ability to develop this uncharted chemical diversity f ....The hidden secondary metabolite biosynthetic potential of fungi. This proposal aims to develop synthetic biology tools to allow rapid access to the hidden metabolites encoded in fungal genomes and discover how they interact with plant and animal hosts. Genome sequencing reveals that fungi harbour vast hidden potential for biosynthesis of bioactive small molecules. The lack of tools to efficiently access this hidden potential has hindered the ability to develop this uncharted chemical diversity for pharmaceutics and agriculture, and understand their biological roles in pathogens. Expected outcomes include sources of bioactive molecules and better management of fungal diseases in crops and humans.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE160100482
Funder
Australian Research Council
Funding Amount
$364,536.00
Summary
Indoleamides as Molecular Interventions for Tuberculosis. This project aims to develop chemical probes capable of inhibiting the transport of essential mycolic acid across the cell wall of Mycobacterium tuberculosis. The emergence of resistant strains of Mycobacterium tuberculosis necessitates the identification of new, validated biological target(s) in the current control of tuberculosis. Preliminary data in this proposal demonstrate the discovery of indoleamides as a novel chemical entity. Dev ....Indoleamides as Molecular Interventions for Tuberculosis. This project aims to develop chemical probes capable of inhibiting the transport of essential mycolic acid across the cell wall of Mycobacterium tuberculosis. The emergence of resistant strains of Mycobacterium tuberculosis necessitates the identification of new, validated biological target(s) in the current control of tuberculosis. Preliminary data in this proposal demonstrate the discovery of indoleamides as a novel chemical entity. Development of these indoleamides may provide insights into a novel mechanism of action that could be targeted in combination with existing antitubercular agents.Read moreRead less
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent ....A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE170100192
Funder
Australian Research Council
Funding Amount
$450,000.00
Summary
Deep Protein Sequencing, Structure and Quantification Facility. This project aims to establish state-of-the-art complementary mass spectrometers to help research into molecular structure and interactions, post-translational modifications, compound stability and availability within complex biological samples. The facility’s complementary mass spectrometers combine high specificity with high sensitivity and ultrafast scanning, and are expected to rapidly discover, identify and characterise biomole ....Deep Protein Sequencing, Structure and Quantification Facility. This project aims to establish state-of-the-art complementary mass spectrometers to help research into molecular structure and interactions, post-translational modifications, compound stability and availability within complex biological samples. The facility’s complementary mass spectrometers combine high specificity with high sensitivity and ultrafast scanning, and are expected to rapidly discover, identify and characterise biomolecules including peptides, proteins and small molecules. The discovery of unknown compounds is expected to improve fundamental understanding of molecular structure and function, provide opportunities for new bio-industries in health and the environment, and generate commercial opportunities through spin-off companies, patents and licensing.Read moreRead less